Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Department of Hepatology & Pancreatology, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
BMC Cancer. 2022 Nov 4;22(1):1134. doi: 10.1186/s12885-022-10207-0.
The distribution of tissue infiltrating lymphocytes has been shown to affect the prognosis of patients with pancreatic cancer in some previous studies. However, the role of peripheral lymphocytes in pancreatic cancer remains debated. The purpose of this study was to analyze the peripheral subtypes of T lymphocytes, and establish their association with the prognosis of patients with pancreatic cancer.
Blood and tissue samples were collected from patients with metastatic pancreatic cancer (n = 54), resectable pancreatic cancer (n = 12), and benign pancreatic cysts (n = 52) between April 2019 and January 2022 and analyzed.
Patients with metastatic pancreatic cancer had a larger proportion of both tumor-suppressive and tumor-promoting cells than those with benign pancreatic cysts. In addition, the proportion of peripheral CD4 T cells positively correlated with the survival of patients with metastatic pancreatic cancer, and the proportion of peripheral CD8CD122 T cells was associated with early mortality (< 90 days). After chemotherapy, CD8CD122 T cells decreased in patients who had a partial response or stable disease. Moreover, by analyzing resected specimens, we first proved that the existence of CD8CD122 T cells in a tumor microenvironment (TME) depends on their proportion in peripheral blood.
Circulating CD8CD122 T cells can be a prognostic indicator in patients with pancreatic cancer.
一些先前的研究表明，组织浸润淋巴细胞的分布会影响胰腺癌患者的预后。然而，外周淋巴细胞在胰腺癌中的作用仍存在争议。本研究旨在分析外周 T 淋巴细胞亚群，并确定其与胰腺癌患者预后的关系。
在 2019 年 4 月至 2022 年 1 月期间，收集了转移性胰腺癌（n=54）、可切除胰腺癌（n=12）和良性胰腺囊肿（n=52）患者的血液和组织样本，并进行了分析。
转移性胰腺癌患者的肿瘤抑制细胞和肿瘤促进细胞比例均高于良性胰腺囊肿患者。此外，外周 CD4 T 细胞比例与转移性胰腺癌患者的生存呈正相关，而外周 CD8CD122 T 细胞比例与早期死亡率（<90 天）相关。化疗后，部分缓解或疾病稳定的患者外周 CD8CD122 T 细胞减少。此外，通过分析切除标本，我们首次证明了肿瘤微环境（TME）中 CD8CD122 T 细胞的存在取决于其在外周血中的比例。
循环 CD8CD122 T 细胞可作为胰腺癌患者的预后指标。
